{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:50:14Z","timestamp":1789541414473,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011475","name":"Cholangiocarcinoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011475","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019608","name":"Lilly Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008167","name":"Pancreatic Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jhepr.2026.101833","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:01:38Z","timestamp":1774339298000},"page":"101833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-6122","authenticated-orcid":false,"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-1886","authenticated-orcid":false,"given":"Paul","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2272-3678","authenticated-orcid":false,"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-7337","authenticated-orcid":false,"given":"Andre","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7147-5703","authenticated-orcid":false,"given":"Daniel H.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101833_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhepr.2026.101833_bib2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101833_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2026.101833_bib4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101833_bib5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u2018prime time\u2019 in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101833_bib6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101833_bib9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.annonc.2022.07.006","article-title":"Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe","volume":"33","author":"Lamarca","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib10","doi-asserted-by":"crossref","first-page":"101452","DOI":"10.1016\/j.jhepr.2025.101452","article-title":"Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging","volume":"7","author":"Danielsen","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101833_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","article-title":"Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma","volume":"29","author":"Yachida","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101833_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.celrep.2015.12.005","article-title":"Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation","volume":"14","author":"Gingras","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhepr.2026.101833_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhepr.2026.101833_bib14","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7051","article-title":"Molecular targets and therapies for ampullary cancer","volume":"22","author":"Patel","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jhepr.2026.101833_bib15","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/cncr.31951","article-title":"Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes","volume":"125","author":"Wong","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2026.101833_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS648","article-title":"HERIZON-BTC-302: a phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced\/metastatic biliary tract cancer (BTC)","volume":"43","author":"Harding","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.jhepr.2026.101833_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104535","article-title":"Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data","volume":"10","author":"Ikushima","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhepr.2026.101833_bib22","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.annonc.2024.09.009","article-title":"Synthetic lethality in MTAP-deleted tumors: a promising avenue through targeted disruption of the protein methylation pathway","volume":"35","author":"Bielo","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib24","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1200\/JCO.2025.43.16_suppl.4078","article-title":"Clinical implication of MDM2 amplification in advanced biliary tract cancer (BTC): a propensity score-matched, retrospective cohort study of 813 patients","volume":"43","author":"Yoon","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.jhepr.2026.101833_bib25","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","article-title":"The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a Phase Ia, first-in-human, dose-escalation study","volume":"13","author":"LoRusso","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101833_bib26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2217\/fon-2023-0963","article-title":"Brightline-2: a phase IIa\/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors","volume":"20","author":"Yoo","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib27","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib28","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib29","first-page":"200","article-title":"Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhepr.2026.101833_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 Study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.101833_bib31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National cancer Institute of the United States, National cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhepr.2026.101833_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2026.101833_bib34","unstructured":"Stata. Stata 12. www.stata.com\/stata12\/[Accessed March 19, 2026]."},{"key":"10.1016\/j.jhepr.2026.101833_bib35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdv483","article-title":"Prognostic factors for progression-free and overall survival in advanced biliary tract cancer","volume":"27","author":"Bridgewater","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.006","volume":"33","author":"Lamarca","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib37","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/hep.31598","article-title":"Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system","volume":"73","author":"Lamarca","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101833_bib38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO-24-01383","article-title":"Swog S1815: a Phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"43","author":"Shroff","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101833_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103328","article-title":"Chemotherapy for advanced gallbladder cancer (GBC): a systematic review and meta-analysis","volume":"163","author":"Azizi","year":"2021","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:36:07Z","timestamp":1785882967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589555926001047"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101833","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101833"}}